UroGen Pharma/$URGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About UroGen Pharma
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Ticker
$URGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
234
ISIN
IL0011407140
Website
UroGen Pharma Metrics
BasicAdvanced
$711M
-
-$3.04
0.67
-
Price and volume
Market cap
$711M
Beta
0.67
52-week high
$17.00
52-week low
$3.42
Average daily volume
4.1M
Financial strength
Current ratio
5.647
Quick ratio
5.132
Long term debt to equity
-268.95
Total debt to equity
-271.994
Interest coverage (TTM)
-7.56%
Profitability
EBITDA (TTM)
-106.578
Gross margin (TTM)
89.68%
Net profit margin (TTM)
-150.68%
Operating margin (TTM)
-116.31%
Effective tax rate (TTM)
-2.34%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-29.80%
Return on equity (TTM)
319.73%
Valuation
Price to revenue (TTM)
7.626
Price to book
-15.29
Price to tangible book (TTM)
-15.29
Price to free cash flow (TTM)
-6.524
Free cash flow yield (TTM)
-15.33%
Free cash flow per share (TTM)
-236.20%
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-5.79%
3-year revenue growth (CAGR)
19.29%
3-year earnings per share growth (CAGR)
-15.50%
What the Analysts think about UroGen Pharma
Analyst ratings (Buy, Hold, Sell) for UroGen Pharma stock.
Bulls say / Bears say
FDA approval of UroGen's bladder cancer drug, Zusduri, offers a non-surgical treatment option, potentially expanding the company's market share. (reuters.com)
Analysts maintain a 'buy' rating for UroGen Pharma, indicating confidence in the company's growth prospects. (etfdailynews.com)
UroGen's innovative gel-based chemotherapy formulation, designed to reduce tumor recurrence, positions the company as a leader in non-invasive cancer treatments. (reuters.com)
The FDA's Oncologic Drugs Advisory Committee voted against the risk/benefit profile of UroGen's UGN-102, leading to a significant stock price decline. (globenewswire.com)
UroGen reported a Q1 loss of $0.92 per share, missing analyst expectations and indicating financial challenges. (nasdaq.com)
A class action lawsuit has been filed against UroGen Pharma, alleging misleading disclosures about its clinical trials, which could lead to legal and financial repercussions. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
UroGen Pharma Financial Performance
Revenues and expenses
UroGen Pharma Earnings Performance
Company profitability
UroGen Pharma News
AllArticlesVideos
URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action
GlobeNewsWire·21 hours ago
UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd.
GlobeNewsWire·3 days ago
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for UroGen Pharma stock?
UroGen Pharma (URGN) has a market cap of $711M as of July 18, 2025.
What is the P/E ratio for UroGen Pharma stock?
The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of July 18, 2025.
Does UroGen Pharma stock pay dividends?
No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next UroGen Pharma dividend payment date?
UroGen Pharma (URGN) stock does not pay dividends to its shareholders.
What is the beta indicator for UroGen Pharma?
UroGen Pharma (URGN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.